Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2018, Article ID 7602962, 8 pages
https://doi.org/10.1155/2018/7602962
Research Article

ShenShuai II Recipe Attenuates Apoptosis and Renal Fibrosis in Chronic Kidney Disease by Increasing Renal Blood Flow and Improving Oxygen Consumption

Meng Wang,1,2 Jing Yang,1,2 Yuan Zhou,1,2 and Chen Wang1,2,3

1Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2Key Laboratory of Liver and Kidney Diseases, Chinese Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
3TCM Institute of Kidney Disease, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Correspondence should be addressed to Chen Wang; moc.621@24gnawnehc

Received 17 September 2018; Revised 20 October 2018; Accepted 3 December 2018; Published 13 December 2018

Academic Editor: Yong C. Boo

Copyright © 2018 Meng Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. J. Hoerger, S. A. Simpson, B. O. Yarnoff et al., “The future burden of CKD in the United States: a simulation model for the CDC CKD initiative,” American Journal of Kidney Diseases, vol. 65, no. 3, pp. 403–411, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. A. C. Webster, E. V. Nagler, R. L. Morton, and P. Masson, “Chronic kidney disease,” The Lancet, vol. 389, no. 10075, pp. 1238–1252, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Wang, L. Tang, Q. Zhu et al., “Hypoxia-inducible factor-1α contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells,” Kidney International, vol. 79, no. 3, pp. 300–310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. X. Zhou, X. Zang, M. Ponnusamy et al., “Enhancer of zeste homolog 2 inhibition attenuates renal fibrosis by maintaining Smad7 and phosphatase and tensin homolog expression,” Journal of the American Society of Nephrology, vol. 27, no. 7, pp. 2092–2108, 2016. View at Publisher · View at Google Scholar
  5. L. G. Fine and J. T. Norman, “Chronic hypoxia as a mechanism of progression of chronic kidney diseases: From hypothesis to novel therapeutics,” Kidney International, vol. 74, no. 7, pp. 867–872, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Deng, T. Tang, P. Singh et al., “Regulation of oxygen utilization by angiotensin II in chronic kidney disease,” Kidney International, vol. 75, no. 2, pp. 197–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Valtin, Renal function:Mechanisms preserving fluid and solute balance in health, vol. 59, Little Brown, Boston, 1983.
  8. M. Fähling, S. Mathia, A. Paliege et al., “Tubular von hippel-lindau knockout protects against rhabdomyolysis-induced AKI,” Journal of the American Society of Nephrology, vol. 24, no. 11, pp. 1806–1819, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Liu and D. Li, “miR-210 Protects Renal Cell Against Hypoxia-induced Apoptosis by Targeting HIF-1 Alpha,” Molecular Medicine, vol. 23, no. 1, p. 1, 2017. View at Publisher · View at Google Scholar
  10. J. Zhou, J. Zhong, Z. Huang et al., “TAK1 mediates apoptosis via p38 involve in ischemia-induced renal fibrosis,” Artificial Cells, Nanomedicine and Biotechnology, pp. 1–10, 2018. View at Publisher · View at Google Scholar
  11. X. Zhou, C. Bai, X. Sun et al., “Puerarin attenuates renal fibrosis by reducing oxidative stress induced-epithelial cell apoptosis via MAPK signal pathways in vivo and in vitro,” Renal Failure, vol. 39, no. 1, pp. 423–431, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Manotham, T. Tanaka, M. Matsumoto et al., “Evidence of Tubular Hypoxia in the Early Phase in the Remnant Kidney Model,” Journal of the American Society of Nephrology, vol. 15, no. 5, pp. 1277–1288, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Mack and M. Yanagita, “Origin of myofibroblasts and cellular events triggering fibrosis,” Kidney International, vol. 87, pp. 297–307, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. J. S. Duffield, “Cellular and molecular mechanisms in kidney fibrosis,” The Journal of Clinical Investigation, vol. 124, no. 6, pp. 2299–2306, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Kimura, M. Iwano, D. F. Higgins et al., “Stable expression of HIF-1α in tubular epithelial cells promotes interstitial fibrosis,” American Journal of Physiology-Renal Physiology, vol. 295, no. 4, pp. F1023–F1029, 2008. View at Publisher · View at Google Scholar
  16. Y. Yang, X. Yu, Y. Zhang et al., “Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury,” Clinical Science, vol. 132, no. 7, pp. 825–838, 2018. View at Publisher · View at Google Scholar
  17. P. Hill, D. Shukla, M. G. B. Tran et al., “Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury,” Journal of the American Society of Nephrology, vol. 19, no. 1, pp. 39–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Rüster and G. Wolf, “Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1189–1199, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Lee, E. A. Shin, J. H. Lee et al., “Caspase inhibitors: a review of recently patented compounds (2013-2015),” Expert Opinion on Therapeutic Patents, vol. 28, no. 1, pp. 47–59, 2018. View at Google Scholar
  20. J. Yang, X. Liu, K. Bhalla et al., “Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked,” Science, vol. 275, no. 5303, pp. 1129–1132, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. T.-J. Liu, Y.-Y. Shi, E.-B. Wang, T. Zhu, and Q. Zhao, “AT1R blocker losartan attenuates intestinal epithelial cell apoptosis in a mouse model of Crohn's disease,” Molecular Medicine Reports, vol. 13, no. 2, pp. 1156–1162, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Chen, R.-S. Huang, X.-X. Yu et al., “Emodin protects against oxidative stress and apoptosis in HK-2 renal tubular epithelial cells after hypoxia/reoxygenation,” Experimental and Therapeutic Medicine, vol. 14, no. 1, pp. 447–452, 2017. View at Publisher · View at Google Scholar · View at Scopus
  23. B. M. Brenner, T. W. Meyer, and T. H. Hostetter, “Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease,” The New England Journal of Medicine, vol. 307, no. 11, pp. 652–659, 1982. View at Publisher · View at Google Scholar · View at Scopus
  24. A. A. Eddy, “Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions,” Journal of the American Society of Nephrology, vol. 5, no. 6, pp. 1273–1287, 1994. View at Google Scholar · View at Scopus
  25. K. A. Nath, “Tubulointerstitial changes as a major determinant in the progression of renal damage,” American Journal of Kidney Diseases, vol. 20, no. 1, pp. 1–17, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Rosenberger, S. Mandriota, J. S. Jürgensen et al., “Expression of hypoxia-inducible factor-1α and -2α in hypoxic and ischemic rat kidneys,” Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1721–1732, 2002. View at Publisher · View at Google Scholar · View at Scopus